Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18402 ↗At a glance
Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Byeong Geun Song and 7 co-authors. Institution: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Major MEDLINE topics: Ferritins, Fatty Liver, Biomarkers. Cited 8 times so far (Crossref); 37 references.
Abstract (original language)
Background
Serum ferritin has been suggested as a potential biomarker associated with disease progression in metabolic dysfunction–associated steatotic liver disease (MASLD).
Aims
We investigated the association between serum ferritin levels and liver‐related events (LREs) in individuals with steatotic liver disease (SLD).
Methods
This cohort study included 17,560 adults with SLD (MASLD [ n = 15,744], MASLD with increased alcohol intake (MetALD) [ n = 1103] and cryptogenic SLD [ n = 713]) without LRE at baseline. A steatotic liver was diagnosed using ultrasound, and LRE was defined as the development of decompensation (ascites, variceal bleeding and hepatic encephalopathy) or hepatocellular carcinoma. Participants were categorised into high (≥ 300 μg/L for males, ≥ 200 μg/L for females) or normal to low (< 300 μg/L for males, < 200 μg/L for females) ferritin levels.
Results
During 211,425 person‐years of follow‐up (median: 12.3 years), 74 incident LRE cases were identified, with 63 cases in MASLD, 10 in MetALD and 1 in cryptogenic SLD. The multivariable‐adjusted hazard ratio (aHR) for LRE comparing individuals with high and normal‐to‐low ferritin level was 3.13 (95% confidence interval [CI] 1.89–5.18). Increased risk of LRE in individuals with high serum ferritin level compared to those with normal to low serum ferritin level was consistent across SLD subtypes (aHR 2.69, 95% CI 1.55–4.67 for MASLD; aHR 5.73, 95% CI 1.31–25.0 for MetALD), and SLD severity assessed by Fibrosis‐4 (FIB‐4) index (aHR 2.38, 95% CI 1.34–4.21 for FIB‐4 ≥ 1.3; aHR 3.13, 95% CI 1.18–8.29 for FIB‐4 < 1.3).
Conclusions
Serum ferritin levels correlated with the risk of LRE in patients with SLD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
ORCID profiles: Byeong Geun Song, Wonseok Kang, Geum-Youn Gwak, Dong Hyun Sinn
Cite
APA
Song, B. G., Goh, M. J., Kang, W., Gwak, G. Y., Paik, Y. H., Choi, M. S., Lee, J. H., & Sinn, D. H. (2025). Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18402
Vancouver
Song BG, Goh MJ, Kang W, Gwak GY, Paik YH, Choi MS, et al. Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18402
BibTeX
@article{Song2025,
author = {Song, Byeong Geun and Goh, Myung Ji and Kang, Wonseok and Gwak, Geum-Youn and Paik, Yong-Han and Choi, Moon Seok and Lee, Joon Hyeok and Sinn, Dong Hyun},
title = {Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18402}
}
EUVIMED